194920-43-9

Upstream product

• 76-05-1 trifluoroacetic acid 
• 194920-62-2 tert-butyl N-(3-{2-[2-(3-aminopropoxy)ethoxy]ethoxy}propyl)carbamate 
• 58-85-5 biotin 
• 194920-63-3 tert-butyl (15-oxo-19-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-trioxa-14-azanonadecyl)carbamate 

Downstream Products

• 1639123-23-1 1-((23R,25R)-23,25-dihydroxy-5,21-dioxo-1-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno-[3,4-d]imidazol-4-yl)-10,13,16-trioxa-6,20-diazaheptacosan-27-yl)-5-(4-fluorophenyl)-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide trifluoroacetate 
• 1565836-02-3 N-(18-(4-(1-benzyl-1H-benzo[d]imidazol-2-yl)phenoxy)-15-oxo-17-(2-phenyl-1H-benzo[d]imidazol-1-yl)-4,7,10-trioxa-14-azaoctadecyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 

Relevant academic research and scientific papers

Thrombin-Inhibiting Anticoagulant Liposomes: Development and Characterization

Many peptides and peptidomimetic drugs suffer from rapid clearance in vivo; this can be reduced by increasing their size through oligomerization or covalent conjugation with polymers. As proof of principle, an alternative strategy for drug oligomerization

Water soluble multi-biotin-containing compounds

Water-soluble discrete multi-biotin-containing compounds with at least three (3) biotin moieties are disclosed. The water-soluble biotin-containing compounds may additionally comprise one or more moieties that confer resistance to cleavage by biotinidase or that is cleavable in vitro or in vivo. The discrete multi-biotin-containing compounds may include a reactive moiety that provides a site for reaction with yet another moiety, such as a targeting, diagnostic or therapeutic functional moiety. Biotinylation reagents comprising water-soluble linker moieties are also disclosed and may additionally comprise a biotinidase protective group. Methods for amplifying the number of sites for binding biotin-binding proteins at a selected target using multi-biotin compounds also are disclosed.